Inhibition of NF-κB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays

Free Radical Biology and Medicine

Volumn 51, Issue 12, 2011, Pages 2249-2258

  Estabrook, Neil C ^a   Chin Sinex, Helen ^a   Borgmann, Anthony J ^a   Dhaemers, Ryan M ^a   Shapiro, Ronald H ^a   Gilley, David ^a   Huda, Nazmul ^a   Crooks, Peter ^b   Sweeney, Christopher ^c   Mendonca, Marc S ^a  

^a INDIANA UNIVERSITY   (United States)

^b University of Kentucky   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

A549; DMAPT; Double strand DNA break repair; Free radicals; H1299; NF B; X rays

Indexed keywords

DIMETHYLAMINOPARTHENOLIDE; DOUBLE STRANDED DNA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL KILLING; CELL PROLIFERATION; COMET ASSAY; CONCENTRATION RESPONSE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; THORAX RADIOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NF-KAPPA B; SESQUITERPENES; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAYS;

MUS MUSCULUS;

EID: 81855178285     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2011.09.029     Document Type: Article

References (45)

1. American Cancer Society Cancer Facts & Figures 2010 2010 Am. Cancer Soc Atlanta
2. H. Brenner, A. Gondos, and V. Arndt Recent major progress in long-term cancer patient survival disclosed by modeled period analysis J. Clin. Oncol. 25 2007 3274 3280 (Pubitemid 47325612)
3. N. Martini, M.S. Bains, M.E. Burt, M.F. Zakowski, P. McCormack, and V.W. Rusch Incidence of local recurrence and second primary tumors in resected stage I lung cancer J. Thorac. Cardiovasc. Surg. 109 1995 120 129
4. M.Y. Chang, and D.J. Sugarbaker Surgery for early stage non-small cell lung cancer Semin. Surg. Oncol. 21 2003 74 84 (Pubitemid 37237416)
5. R. Rami-Porta, D. Ball, J. Crowley, D.J. Giroux, J. Jett, and W.D. Travis The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer J. Thorac. Oncol. 2 2007 593 602 (Pubitemid 47171780)
6. R. Timmerman, L. Papiez, R. McGarry, L. Likes, C. DesRosiers, and S. Frost Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer Chest 124 2003 1946 1955 (Pubitemid 37433596)
7. H. Onishi, T. Araki, H. Shirato, Y. Nagata, M. Hiraoka, and K. Gomi Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study Cancer 101 2004 1623 1631 (Pubitemid 39318910)
8. R.C. McGarry, L. Papiez, M. Williams, T. Whitford, and R.D. Timmerman Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study Int. J. Radiat. Oncol. Biol. Phys. 63 2005 1010 1015 (Pubitemid 41505277)
9. R.D. Timmerman, C. Park, and B.D. Kavanagh The North American experience with stereotactic body radiation therapy in non-small cell lung cancer J. Thorac. Oncol. 2 2007 S101 S112
10. H. Onishi, H. Shirato, Y. Nagata, M. Hiraoka, M. Fujino, and K. Gomi Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study J. Thorac. Oncol. 2 2007 S94 S100
11. R. Timmerman, R. Abdulrahman, B.D. Kavanagh, and J.L. Meyer Lung cancer: a model for implementing stereotactic body radiation therapy into practice Front. Radiat. Ther. Oncol. 40 2007 368 385
12. R. Timmerman, M. Bastasch, D. Saha, R. Abdulrahman, W. Hittson, and M. Story Optimizing dose and fractionation for stereotactic body radiation therapy: normal tissue and tumor control effects with large dose per fraction Front. Radiat. Ther. Oncol. 40 2007 352 365
13. R. Timmerman, R. McGarry, C. Yiannoutsos, L. Papiez, K. Tudor, and J. DeLuca Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J. Clin. Oncol. 24 2006 4833 4839 (Pubitemid 46630909)
14. F.J. Lagerwaard, C.J. Haasbeek, E.F. Smit, B.J. Slotman, and S. Senan Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer Int. J. Radiat. Oncol. Biol. Phys. 70 2008 685 692
15. S. Wang, Z. Liao, X. Wei, H.H. Liu, S.L. Tucker, and C.S. Hu Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT) Int. J. Radiat. Oncol. Biol. Phys. 66 2006 1399 1407
16. F.L. Reboul Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data Hematol. Oncol. Clin. North Am. 18 2004 41 53 (Pubitemid 38201548)
17. N. O'Rourke, and F. Macbeth Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence Clin. Oncol. (R. Coll. Radiol.) 22 2010 347 355
18. I. Okamoto Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan Int. J. Clin. Oncol. 13 2008 112 116 (Pubitemid 351668177)
19. M. Provencio, A. Sanchez, P. Garrido, and F. Valcarcel New molecular targeted therapies integrated with radiation therapy in lung cancer Clin. Lung Cancer 11 2010 91 97
20. H. Nakshatri, P. Bhat-Nakshatri, D.A. Martin, R.J. Goulet Jr., and G.W. Sledge Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth Mol. Cell. Biol. 17 1997 3629 3639 (Pubitemid 27281838)
21. M. Jung, and A. Dritschilo NF-kappa B signaling pathway as a target for human tumor radiosensitization Semin. Radiat. Oncol. 11 2001 346 351 (Pubitemid 32959669)
22. C. Sweeney, L. Li, R. Shanmugam, P. Bhat-Nakshatri, V. Jayaprakasan, and L.A. Baldridge Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate Clin. Cancer Res. 10 2004 5501 5507 (Pubitemid 39100488)
23. C. Nakanishi, and M. Toi Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs Nat. Rev. Cancer 5 2005 297 309 (Pubitemid 40488635)
24. Y. Habraken, and J. Piette NF-kappaB activation by double-strand breaks Biochem. Pharmacol. 72 2006 1132 1141
25. H.J. Kim, N. Hawke, and A.S. Baldwin NF-kappaB and IKK as therapeutic targets in cancer Cell Death Differ. 13 2006 738 747
26. F. Li, and G. Sethi Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy Biochim. Biophys. Acta 1805 2010 167 180
27. M.S. Mendonca, H. Chin-Sinex, J. Gomez-Millan, N. Datzman, M. Hardacre, and K. Comerford Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair Radiat. Res. 168 2007 689 697 (Pubitemid 351295105)
28. C. Watson, D.A. Miller, H. Chin-Sinex, A. Losch, W. Hughes, and C. Sweeney Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells Radiat. Res. 171 2009 389 396
29. S. Heptinstall, W.A. Groenewegen, P. Spangenberg, and W. Losche Inhibition of platelet behaviour by feverfew: a mechanism of action involving sulphydryl groups Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. 115 1988 447 449
30. N.H. Nam Naturally occurring NF-kappaB inhibitors Mini Rev. Med. Chem. 6 2006 945 951
31. H. Ichikawa, Y. Nakamura, Y. Kashiwada, and B.B. Aggarwal Anticancer drugs designed by mother nature: ancient drugs but modern targets Curr. Pharm. Des. 13 2007 3400 3416 (Pubitemid 350201674)
32. P.M. Bork, M.L. Schmitz, M. Kuhnt, C. Escher, and M. Heinrich Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB FEBS Lett. 402 1997 85 90 (Pubitemid 27056030)
33. S.P. Hehner, T.G. Hofmann, W. Droge, and M.L. Schmitz The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex J. Immunol. 163 1999 5617 5623
34. Y. Sun, D.K. St Clair, F. Fang, G.W. Warren, V.M. Rangnekar, and P.A. Crooks The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN Mol. Cancer Ther. 6 2007 2477 2486 (Pubitemid 47480413)
35. M.L. Guzman, R.M. Rossi, S. Neelakantan, X. Li, C.A. Corbett, and D.C. Hassane An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells Blood 110 2007 4427 4435 (Pubitemid 351377809)
36. R. Shanmugam, P. Kusumanchi, L. Cheng, P. Crooks, S. Neelakantan, and W. Matthews A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species Prostate 70 2010 1074 1086
37. R. Shanmugam, P. Kusumanchi, H. Appaiah, L. Cheng, P. Crooks, and S. Neelakantan A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species Int. J. Cancer 128 2011 2481 2494
38. M.M. Elkind, and H. Sutton X-ray damage and recovery in mammalian cells in culture Nature 184 1959 1293 1295
39. M.M. Elkind, and H. Sutton Radiation response of mammalian cells grown in culture. 1. Repair of X-ray damage in surviving Chinese hamster cells Radiat. Res. 13 1960 556 593
40. P.L. Olive, and J.P. Banath The comet assay: a method to measure DNA damage in individual cells Nat. Protoc. 1 2006 23 29
41. N. Huda, H. Tanaka, M.S. Mendonca, and D. Gilley DNA damage-induced phosphorylation of TRF2 is required for the fast pathway of DNA double-strand break repair Mol. Cell. Biol. 29 2009 3597 3604
42. P.L. Olive Impact of the comet assay in radiobiology Mutat. Res. 681 2009 13 23
43. G. Iliakis, H. Wang, A.R. Perrault, W. Boecker, B. Rosidi, and F. Windhofer Mechanisms of DNA double strand break repair and chromosome aberration formation Cytogenet. Genome Res. 104 2004 14 20 (Pubitemid 38721048)
44. P. Pozarowski, D.H. Halicka, and Z. Darzynkiewicz NF-kappaB inhibitor sesquiterpene parthenolide induces concurrently atypical apoptosis and cell necrosis: difficulties in identification of dead cells in such cultures Cytometry 54A 2003 118 124 (Pubitemid 37521488)
45. J. Wen, K.R. You, S.Y. Lee, C.H. Song, and D.G. Kim Oxidative stress-mediated apoptosis: the anticancer effect of the sesquiterpene lactone parthenolide J. Biol. Chem. 277 2002 38954 38964 (Pubitemid 35154761)